Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& R% D/ {9 ]' G
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ; j) s4 e4 }, Z% r
+ Author Affiliations7 L k1 l6 P2 c* _$ w# g
3 r& ~1 I' p) Y5 Q4 P0 |1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 7 Y) N. X% X1 a* ]9 l8 j
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ @( M1 y/ b* x2 z* O; N1 f3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
* R) h2 X9 Q- p0 G. k4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 @5 R* V' O1 a. m0 ?7 y) L7 y
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
- A5 y8 ~3 s j$ F- D7 N6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 4 I! Z$ w0 f( I+ [- L3 a4 q3 a
7Kinki University School of Medicine, Osaka 589-8511, Japan
% o. t- _; ?' W9 k- D8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 b8 a7 K8 a2 s7 i1 p; h
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& J$ A) E& |0 ~, dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
; |4 C3 X+ ?, j1 I3 v2 x# H9 rAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / `* {2 @9 K; q; ]1 H4 @/ _4 t8 x
( G7 r5 C# s+ d$ K" }) i |